The path to appropriate biosimilar management by Jim Rebello May 10, 2021 Biosimilar, Biosimilar Management, Biosimilars, FDA, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, Medical Benefit, Oncology Biosimilars, Specialty Pharmacy
